Alx Oncology Holdings (ALXO) Cash & Equivalents (2019 - 2026)

Alx Oncology Holdings has reported Cash & Equivalents for 8 years, with the latest figure at $32.3 million in Q1 2026.

• Quarterly Cash & Equivalents rose 56.61% year-over-year to $32.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.3 million (up 56.61% YoY) and the FY2025 annual result came in at $16.4 million, down 6.8% from the prior year.
• Cash & Equivalents advanced to $32.3 million in Q1 2026 per ALXO's latest filing, from $16.4 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $159.1 million in Q1 2022 and troughed at $14.0 million in Q1 2024.
• A 5-year average of $37.8 million and a median of $22.4 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents plunged 87.26% in 2022, then soared 56.61% in 2026.
• Over 5 years, Cash & Equivalents stood at $48.8 million in 2022, then slumped by 54.11% to $22.4 million in 2023, then fell by 21.6% to $17.6 million in 2024, then declined by 6.8% to $16.4 million in 2025, then jumped by 97.18% to $32.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $32.3 million, $16.4 million, and $23.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.